Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H13ClN2O2.H2O4S |
| Molecular Weight | 398.818 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=CC=CC=C3
InChI
InChIKey=XNBFXTXDZMWXMN-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O2.H2O4S/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10;1-5(2,3)4/h2-9,15,20H,1H3;(H2,1,2,3,4)
DescriptionSources: http://www.drugbank.ca/drugs/DB00231Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018163s054lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00231
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018163s054lbl.pdf
Temazepam is a benzodiazepine used as a hypnotic agent in the management of insomnia. Temazepam produces CNS depression at limbic, thalamic, and hypothalamic levels of the CNS. Temazepam increases the affinity of the neurotransmitter gamma-aminobutyric acid (GABA) for GABA receptors by binding to benzodiazepine receptors. Results are sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action. Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. Temazepam is used for the short-term treatment of insomnia (generally 7-10 days).
CNS Activity
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
865 ng/mL |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
964 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1560 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2574013 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1800 ng × h/mL |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.8 h |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
10.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2574013 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4% |
30 mg 1 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8181199 |
26 mg single, intravenous dose: 26 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
TEMAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
26 mg single, intravenous Dose: 26 mg Route: intravenous Route: single Dose: 26 mg Sources: |
healthy, 18 - 24 years Health Status: healthy Age Group: 18 - 24 years Sex: M+F Sources: |
|
40 mg single, oral |
unhealthy, 42 years (range: 22 - 59 years) n = 14 Health Status: unhealthy Age Group: 42 years (range: 22 - 59 years) Sex: M+F Population Size: 14 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Direct LC analysis of five benzodiazepines in human urine and plasma using an ADS restricted access extraction column. | 2001 Dec |
|
| Culture of porcine hepatocytes: the dogma of exogenous matrix revisited. | 2001 Jul |
|
| Ethanol, errors, and the speed-accuracy trade-off. | 2001 Jul-Aug |
|
| Urinary excretion of diazepam metabolites in healthy volunteers and drug users. | 2001 May |
|
| The use of vitreous humor as an alternative to whole blood for the analysis of benzodiazepines. | 2001 May |
|
| Treatment of insomnia in hospitalized patients. | 2001 Nov |
|
| Drugs in postmortem adipose tissues: evidence of antemortem deposition. | 2001 Oct 1 |
|
| Drug related deaths in the Strathclyde region of Scotland, 1995-1998. | 2001 Oct 15 |
|
| Determination of partial solubility parameters of five benzodiazepines in individual solvents. | 2001 Oct 9 |
|
| Prevention of fall from the bed of spinal cord injury patients. | 2001 Sep |
|
| Experience with urine drug testing by the Correctional Service of Canada. | 2001 Sep 15 |
|
| Use of night-time benzodiazepines in an elderly inpatient population. | 2002 Apr |
|
| Digit loss following misuse of temazepam. | 2002 Apr 15 |
|
| Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. | 2002 Dec |
|
| Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. | 2002 Dec 5 |
|
| Severe vein damage caused by Temezepam injecting. | 2002 Feb |
|
| Alcohol and benzodiazepines in fatal poisonings. | 2002 Jul |
|
| Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? | 2002 Jul |
|
| Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation. | 2002 Mar |
|
| Commentary on: Dou C, Bournique J, Zinda M, Gnezda M, Nally A, Salamone S. Comparison of rates of hydrolysis of lorazepam-glucuronide, oxazepam-glucuronide and temazepam-glucuronide catalyzed by E. coli beta-glucuronidase using the on-line benzodiazepine screening immunoassay on the Roche/Hitachi 917 analyzer. | 2002 Mar |
|
| Direct determination of benzodiazepines in biological fluids by restricted-access solid-phase microextraction. | 2002 Mar 1 |
|
| [Fatal outcome of poisoning with the benzodiazepines flunitrazepam and diazepam]. | 2002 Mar-Apr |
|
| CNS effects of sumatriptan and rizatriptan in healthy female volunteers. | 2002 May |
|
| Melatonin and zopiclone: the relationship between sleep propensity and body temperature. | 2002 May 1 |
|
| Long term benzodiazepine use for insomnia in patients over the age of 60: discordance of patient and physician perceptions. | 2002 May 8 |
|
| Insomnia. Diagnosis and management. | 2002 Nov |
|
| Determination of the enantiomerization energy barrier of some 3-hydroxy-1,4-benzodiazepine drugs by supercritical fluid chromatography. | 2002 Nov 5 |
|
| Simple and sensitive liquid chromatography/tandem mass spectrometry method for the determination of diazepam and its major metabolites in rat cerebrospinal fluid. | 2003 |
|
| Analytical developments in toxicological investigation of drug-facilitated sexual assault. | 2003 Aug |
|
| Improving daytime sleep with temazepam as a countermeasure for shift lag. | 2003 Feb |
|
| Temazepam, but not zolpidem, causes orthostatic hypotension in astronauts after spaceflight. | 2003 Jan |
|
| Association of benzodiazepine injection with the prescription of temazepam capsules. | 2003 Jun |
|
| Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. | 2003 Jun |
|
| Case report: severe mercuric sulphate poisoning treated with 2,3-dimercaptopropane-1-sulphonate and haemodiafiltration. | 2003 Jun |
|
| Effects of diazepam and its metabolites on nocturnal melatonin secretion in the rat pineal and Harderian glands. A comparative in vivo and in vitro study. | 2003 Mar |
|
| Errors in performance testing: a comparison of ethanol and temazepam. | 2003 Mar |
|
| Interaction of alcohol and drugs in fatal poisonings. | 2003 May |
|
| Fast analysis using monolithic columns coupled with high-flow on-line extraction and electrospray mass spectrometric detection for the direct and simultaneous quantitation of multiple components in plasma. | 2003 May 25 |
|
| [Comparative kinetics of 3-hydroxyphenazepam and its metabolism during transdermal and intravenous administration]. | 2003 May-Jun |
|
| Effects of after-midnight intake of zolpidem and temazepam on driving ability in women with non-organic insomnia. | 2003 Nov |
|
| Chiral separations using polymeric surfactants and polyelectrolyte multilayers in open-tubular capillary electrochromatography. | 2003 Nov 15 |
|
| [Benzodiazepines and forensic aspects]. | 2003 Nov-Dec |
|
| [Signopam treatment of insomnia in patients with somatic pathology]. | 2004 |
|
| Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. | 2004 Aug |
|
| Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. | 2004 Feb |
|
| A postmarketing study of relative abuse liability of hypnotic sedative drugs. | 2004 Feb |
|
| CNS effects of sumatriptan and rizatriptan. | 2004 Jan |
|
| Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. | 2004 Jul |
|
| Sleep-inducing pharmaceuticals: a comparison of melatonin, zaleplon, zopiclone, and temazepam. | 2004 Jun |
|
| Effects of zolpidem and temazepam on driving ability. | 2004 Nov |
Patents
Sample Use Guides
While the recommended usual adult dose is 15 mg before retiring, 7.5 mg may be sufficient for some patients, and others may need 30 mg. In transient insomnia, a 7.5 mg dose may be sufficient to improve sleep latency. In elderly or debilitated patients, it is recommended that therapy be initiated with 7.5 mg until individual responses are determined.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
17311-34-1
Created by
admin on Sat Dec 16 01:35:59 GMT 2023 , Edited by admin on Sat Dec 16 01:35:59 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
I1HX8463I0
Created by
admin on Sat Dec 16 01:35:59 GMT 2023 , Edited by admin on Sat Dec 16 01:35:59 GMT 2023
|
PRIMARY | |||
|
121225695
Created by
admin on Sat Dec 16 01:35:59 GMT 2023 , Edited by admin on Sat Dec 16 01:35:59 GMT 2023
|
PRIMARY | |||
|
31677-86-8
Created by
admin on Sat Dec 16 01:35:59 GMT 2023 , Edited by admin on Sat Dec 16 01:35:59 GMT 2023
|
PRIMARY | |||
|
DBSALT002271
Created by
admin on Sat Dec 16 01:35:59 GMT 2023 , Edited by admin on Sat Dec 16 01:35:59 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
